Lingjiao Zhang

Mepolizumab benefits severe asthma regardless of medium-dose or high-dose inhaled corticosteroids at baseline

Cristiano Caruso, Andrew Smith, Manish Patel, Giorgio Walter Canonica et autres

Background Severe asthma treatment commonly entails progression from medium- to high-dose maintenance inhaled corticosteroids (mICS) before biologic therapies are considered. The objective of this post hoc analysis of REALITI-A was to assess the impact of mepolizumab on clinical outcomes when initiated in …

Mepolizumab reduces healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps: a linked EMR and claims-based pre-post study

Anna Swenson, Waseem Ahmed, Jared Silver, Shiyuan Zhang et autres

BACKGROUND: Real-world evidence on the effectiveness of mepolizumab at reducing healthcare resource utilization (HCRU) and clinical symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) is limited. METHODS: This real-world study used linked electronic medical record and claims data from the …

us, gb (code pays fourni par la source)

S164 Mepolizumab improves and sustains asthma control and lung function in patients with severe asthma, independent of baseline IgE and FeNO in the real world: 2-year results from REALITI-A

Giorgio Walter Canonica, M. C. Liu, Charles Pilette, Jong‐Koo Lee et autres

Introduction and objectives: REALITI-A study demonstrated mepolizumab effectiveness independent of immunoglobulin-E (IgE) and fractional exhaled nitric oxide (FeNO) levels in patients with severe asthma in preliminary 1-year analyses. However, additional longer-term real-world evidence on the effect of mepolizumab on asthma control and …

it, us, be, ca, gb (code pays fourni par la source)

P199 Mepolizumab improves and sustains asthma control and lung function in patients with severe asthma independent of baseline blood eosinophil count in the real world: results from REALITI-A at 2 years

Giorgio Walter Canonica, M. C. Liu, Charles Pilette, Jong‐Koo Lee et autres

Introduction and Objectives Preliminary 1-year analyses from the real-world REALITI-A study demonstrated mepolizumab improvements in asthma control and lung function, a key outcome measurement, with mepolizumab treatment across blood eosinophil count (BEC) levels, in patients with severe asthma. However, additional real-world evidence …

it, us, be, ca, gb (code pays fourni par la source)

Impact of primary diagnosis of SA or CRSwNP on comorbid patients – Baseline features in the RESPONSE study

Florence Schleich, Jannis Constantinidis, Camille Taillé, Isam Alobid et autres

Background: Severe asthma (SA) and chronic rhinosinusitis with nasal polyps (CRSwNP) are chronic airway inflammatory conditions that coexist in 40-65% of patients. Aims: To assess the baseline features of patients with SA and comorbid NP or severe CRSwNP with comorbid asthma, in …

be, gr, fr, es, de, us, gb (code pays fourni par la source)

REIMAGINE: A prospective real-world evaluation of clinical remission in patients with severe asthma treated with mepolizumab in a timely manner

Florence Schleich, Peter Hugo Howarth, Lisette Delgado Sanchez, Francesca Puggioni et autres

Background: Clinical remission (CR) in severe asthma (SA) is an ambitious and achievable treatment goal; further prospective real-world analyses are needed to determine the impact of timely intervention on achieving CR. Aims: REIMAGINE prospectively evaluates the proportion of a subset of patients …

be, us, it, ca, es, gb, nl (code pays fourni par la source)

Mepolizumab reduced healthcare resource utilization and improved work productivity in patients with severe asthma during the REALITI-A 2-year study

Giorgio Walter Canonica, Arnaud Bourdin, Erika Dianne Penz, Lingjiao Zhang et autres

Objective To assess the real-world impact of mepolizumab on healthcare resource utilization (HCRU) and work productivity and activity impairment (WPAI) in patients with severe asthma.Methods Asthma-related HCRU and WPAI were assessed over 2 years in the REALITI-A study—an international prospective, observational, cohort …

it, fr, ca, gb, us (code pays fourni par la source)

Mepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two years

Giorgio Walter Canonica, Diego Bagnasco, Jason K. Lee, Geoffrey Lowell Chupp et autres

Background Although clinical trial evidence exists, there is limited awareness of the real-world effectiveness of mepolizumab in patients with severe asthma and blood eosinophil counts (BEC) ≥150–<300 cells·μL −1 . Methods REALITI-A, an international, prospective, single-arm, observational cohort study enrolled patients with …

it, ca, us, be, gb (code pays fourni par la source)

Impact of Demographics on Mepolizumab Effectiveness in Severe Asthma: One-Year REALITI-A Subanalysis

Geoffrey Lowell Chupp, Liam Gabriel Heaney, Girolamo Pelaia, Carlos Almonacid et autres

us, gb, bd, it, es, de, be (code pays fourni par la source)

Impact of atopic status, prior omalizumab use and baseline blood eosinophil count alone and in combination with total serum IgE on maintenance OCS reduction outcomes in patients with severe asthma treated with mepolizumab in the REALITI-A study

Min Liu, Rekha Chaudhuri, Geoffrey Lowell Chupp, Liam Gabriel Heaney et autres

us, gb, ca, be, fr (code pays fourni par la source)

Mepolizumab Improves and Sustains Clinical Benefits in Patients With Severe Asthma, Independent of Blood Eosinophil Count at Baseline: Real-World Analysis of REALITI-A Results at 2 Years

Mark Liu, JASON KAI WEI LEE, Steven A. Gould, Stephen G. Noorduyn et autres

us, gb, ca (code pays fourni par la source)

Mepolizumab Improves and Sustains Clinical Benefits in Patients With Severe Asthma, Independent of IgE and FeNO at Baseline: Real-World Analysis of REALITI-A Results at 2 Years

JASON KAI WEI LEE, Mark Liu, Steven A. Gould, Stephen G. Noorduyn et autres